Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANNEYD M AVALOS-PENA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1962863266
CMS profile
1840767
Location
DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,813.84

99 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,813.84 99

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANNEYD M AVALOS-PENA

NPI 1962863266 · CMS profile ID 1840767

Allopathic & Osteopathic Physicians / Internal Medicine

DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962863266?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANNEYD M AVALOS-PENA, NPI 1962863266, CMS profile ID 1840767. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962863266?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ANNEYD M AVALOS-PENA, NPI 1962863266, CMS profile ID 1840767. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962863266?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ANNEYD M AVALOS-PENA, NPI 1962863266, CMS profile ID 1840767, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1962863266?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

99 matching records · $1,813.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 99 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–99 of 99.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $15.9206/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811448923 CMS
AbbVie Inc. $14.9806/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793940741 CMS
Amgen Inc. $18.2006/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826295589 CMS
Amarin Pharma Inc. $15.3906/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815144757 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.6105/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763779664 CMS
AbbVie Inc. $15.6005/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793940737 CMS
Novo Nordisk Inc $15.8505/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811304273 CMS
Xeris Pharmaceuticals, Inc. $17.2405/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837410689 CMS
Merck Sharp & Dohme Corporation $22.6005/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848498519 CMS
Amgen Inc. $11.3505/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826295585 CMS
SANOFI-AVENTIS U.S. LLC $19.0605/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843687877 CMS
AbbVie Inc. $19.6705/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793940733 CMS
AbbVie Inc. $13.8005/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793940729 CMS
AstraZeneca Pharmaceuticals LP $23.1805/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829380125 CMS
GlaxoSmithKline, LLC. $17.1105/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803202591 CMS
Medtronic, Inc. $15.4905/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815740051 CMS
AbbVie Inc. $17.0305/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793940725 CMS
GlaxoSmithKline, LLC. $20.4605/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802941185 CMS
Amgen Inc. $10.5805/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826295581 CMS
Medtronic, Inc. $12.8304/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815740039 CMS
Novartis Pharmaceuticals Corporation $20.0004/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812594639 CMS
AbbVie Inc. $22.4204/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793940721 CMS
Medtronic, Inc. $12.3804/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815708551 CMS
Lilly USA, LLC $18.6404/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818950307 CMS
AbbVie Inc. $4.7104/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793940717 CMS
Novo Nordisk Inc $18.0904/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811150215 CMS
SANOFI-AVENTIS U.S. LLC $14.2504/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843687873 CMS
Novo Nordisk Inc $14.2504/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811448917 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.1204/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763779666 CMS
Merck Sharp & Dohme Corporation $22.3104/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848614687 CMS
Novo Nordisk Inc $16.0203/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811694203 CMS
Novartis Pharmaceuticals Corporation $21.6703/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812594637 CMS
Amgen Inc. $18.2203/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825149949 CMS
AbbVie Inc. $6.6703/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793940713 CMS
Novo Nordisk Inc $17.3303/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811593043 CMS
AbbVie Inc. $15.9203/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793940709 CMS
Janssen Pharmaceuticals, Inc $19.0203/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788872663 CMS
Merck Sharp & Dohme Corporation $23.8703/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848457225 CMS
Amgen Inc. $5.9002/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826295577 CMS
Lilly USA, LLC $15.0002/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818947677 CMS
Amgen Inc. $16.9702/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826295573 CMS
AstraZeneca Pharmaceuticals LP $23.5302/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829553161 CMS
Corcept Therapeutics $17.8602/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837519977 CMS
Lilly USA, LLC $15.0202/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818943643 CMS
Amgen Inc. $17.4502/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825149941 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.2502/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763779668 CMS
Lilly USA, LLC $20.8001/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818896773 CMS
SANOFI-AVENTIS U.S. LLC $18.0301/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843687843 CMS
Novo Nordisk Inc $16.4301/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810775599 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,874.51 83
PY2021 $1,813.84 99
PY2022 $1,789.91 87
PY2023 $408.85 17
PY2024 $601.94 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,233,378.84 41
PY2024 Principal investigator $194,841.92 17
PY2023 Principal investigator $8,611.56 4
PY2022 Principal investigator $18,460.00 5
PY2021 Principal investigator $41,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 F. Hoffmann-La Roche AG $3,734.50 12/09/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603466
Principal investigator 1 Mylan Pharmaceuticals Inc. $24,385.35 12/09/2025 Non-covered Recipient Entity
Clinical Pharmacology of Miami, LLC, a subsidiary of ERG Holding Company, LLC
MR-139A-01-OMZ-1001 No dispute reported 06/30/2026 1238531884
Principal investigator 1 Genentech, Inc. $2,500.00 11/21/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603545
Principal investigator 1 Genentech, Inc. $2,500.00 11/21/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603553
Principal investigator 1 Mylan Pharmaceuticals Inc. $102,227.25 11/21/2025 Non-covered Recipient Entity
Clinical Pharmacology of Miami, LLC, a subsidiary of ERG Holding Company, LLC
FFUV-IHP-1003 No dispute reported 06/30/2026 1238531814
Principal investigator 1 Mylan Pharmaceuticals Inc. $85,189.38 11/14/2025 Non-covered Recipient Entity
Clinical Pharmacology of Miami, LLC, a subsidiary of ERG Holding Company, LLC
FFUV-IHP-1003 No dispute reported 06/30/2026 1238531812
Principal investigator 1 Genentech, Inc. $213.87 11/07/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603549
Principal investigator 1 Novartis Pharmaceuticals Corporation $159,021.40 11/07/2025 Non-covered Recipient Entity
CLINICAL PHARMACOLOGY OF MIAMI
A Phase 1, open-label study to investigate the pharmacokinetics and safety of remibrutinib (LOU064) in participants with severe renal impairment compared to matched healthy participants with normal renal function No dispute reported 06/30/2026 1190306253
Principal investigator 1 Mylan Pharmaceuticals Inc. $134,826.51 10/28/2025 Non-covered Recipient Entity
Clinical Pharmacology of Miami, LLC, a subsidiary of ERG Holding Company, LLC
BUPI-ISL-1004 No dispute reported 06/30/2026 1238531838
Principal investigator 1 Genentech, Inc. $100.00 10/27/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603536
Principal investigator 1 Genentech, Inc. $16,334.64 10/27/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603540
Principal investigator 1 ModernaTX, Inc. $1,375.00 10/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252992362
Principal investigator 1 ModernaTX, Inc. $750.00 10/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252992368
Principal investigator 1 ModernaTX, Inc. $2,254.50 10/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252992370
Principal investigator 1 ModernaTX, Inc. $769.50 10/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252992372
Principal investigator 1 ModernaTX, Inc. $376.65 10/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252992374
Principal investigator 1 ModernaTX, Inc. $500.00 10/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252992378
Principal investigator 1 ModernaTX, Inc. $900.00 10/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252992380
Principal investigator 1 ModernaTX, Inc. $5,000.00 10/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252992382
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252992364
Principal investigator 1 ModernaTX, Inc. $750.00 09/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252992366
Principal investigator 1 ModernaTX, Inc. $1,750.00 09/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252992376
Principal investigator 1 AstraZeneca UK Limited $134,943.50 08/29/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY, LLC
A SingleDose NonRandomised OpenLabel ParallelGroup Study to Investigate the Effects of Renal Impairment on the Pharmacokinetics Safety and Tolerability of Opemalirsen AZD2373 No dispute reported 06/30/2026 1185548201
Principal investigator 1 Ipsen Pharma SAS $3,057.50 08/21/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Development of Post-Stroke Spasticity No dispute reported 06/30/2026 1184303243
Principal investigator 1 F. Hoffmann-La Roche AG $90.00 07/30/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603417
Principal investigator 1 F. Hoffmann-La Roche AG $9,958.50 07/30/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603422
Principal investigator 1 F. Hoffmann-La Roche AG $2,138.00 07/30/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603426
Principal investigator 1 F. Hoffmann-La Roche AG $812.50 07/30/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603431
Principal investigator 1 F. Hoffmann-La Roche AG $2,423.00 07/14/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603449
Principal investigator 1 F. Hoffmann-La Roche AG $1,311.50 07/07/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603457
Principal investigator 1 F. Hoffmann-La Roche AG $21,242.50 07/01/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603435
Principal investigator 1 F. Hoffmann-La Roche AG $2,195.50 07/01/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603440
Principal investigator 1 F. Hoffmann-La Roche AG $3,120.00 07/01/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603443
Principal investigator 1 F. Hoffmann-La Roche AG $7,875.00 07/01/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603453
Principal investigator 1 F. Hoffmann-La Roche AG $7,097.00 07/01/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 No dispute reported 06/30/2026 1211603462
Principal investigator 1 Mylan Pharmaceuticals Inc. $134,372.70 05/13/2025 Non-covered Recipient Entity
Clinical Pharmacology of Miami, LLC, a subsidiary of ERG Holding Company, LLC
MR-139A-01-OMZ-1001 No dispute reported 06/30/2026 1238531888
Principal investigator 1 ModernaTX, Inc. $2,000.00 05/08/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252992384
Principal investigator 1 Mylan Pharmaceuticals Inc. $104,662.95 05/06/2025 Non-covered Recipient Entity
Clinical Pharmacology of Miami, LLC, a subsidiary of ERG Holding Company, LLC
MR-139A-01-OMZ-1001 No dispute reported 06/30/2026 1238531886
Principal investigator 1 Amgen Inc. $33,273.00 04/24/2025 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS INC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246640575
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $203,621.89 02/26/2025 Non-covered Recipient Entity
Erg Holding Company Llc
A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis No dispute reported 06/30/2026 1235997463
Principal investigator 1 Amgen Inc. $12,225.25 01/21/2025 Non-covered Recipient Entity
D AND H DORAL RESEARCH CENTERS
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246640571